Specialty Pharmacy

A targeted therapeutic approach shrank tumors caused by medulloblastoma, a deadly form a pediatric brain cancer.

The generic drug (Wixela Inhub, Mylan) is indicated to treat patients with asthma and chronic obstructive pulmonary disease, including bronchitis and emphysema.

Individuals who perceive themselves to be at a high risk of HIV are more likely to accept pre-exposure prophylaxis (PrEP) than their peers.

Senate Finance Committee Chairman Senator Charles Grassley pledged to “get to the bottom of the insulin price problem.”

Analysis shows prices among all insulin types and products increased steadily between 2012 and 2016.

Top news of the day across the health care landscape.

Two recent studies analyzed factors that impacted response to therapy in patients with multiple myeloma.

Ibrutinub plus obinutuzumab is the first FDA-approved non-chemotherapy combination regimen for chronic lymphocytic lymphoma and small lymphocytic lymphoma.

Better strategies are needed to adequately identify and prevent opportunistic infections and related deaths in patients with advanced HIV.

Top news of the day across the health care landscape.

Robert F. Sidonio Jr, MD, assistant professor of pediatrics at Emory University, Children's Healthcare of Atlanta, gives an overview of the different hemophilia therapies and recent improvements in the treatment landscape.

Post-cure care for hepatitis C can reduce the risk of liver disease progression in those with advanced fibrosis and ongoing risk factors for liver injury.

Selecting an accreditation agency should be determined by the local business environment and needs.

Top news of the week from Specialty Pharmacy Times.

A look at last week's top stories in the world of pharmacy.

Top news of the day across the health care landscape.

Rituximab is approved by the FDA for the treatment of adults with rheumatoid arthritis, non-Hodgkin's lymphoma, chronic lymphocytic leukemia, pemphigus vulgaris, granulomatosis with polyangiitis and microscopic polyangiitis.

Younger cancer survivors and those with high deductible private insurance plans experienced the greatest financial burden.

Top news of the day across the health care landscape.

Nonmyeloablative hematopoietic stem cell transplant found to prolong time to multiple sclerosis disease progression compared with disease-modifying therapies.

An inhaled medication for a disease that does not affect the lungs may prove to be a promising concept in the treatment of chronic diseases.

The new indication would allow treatment-experienced patients with HIV to switch to Pifeltro in combination with other HIV medications or Delstrigo.

Universal hepatitis screening may be warranted to identify patients with cancer who have undiagnosed viral infections.

This is the first time an anti-PD-1 therapy has demonstrated a survival benefit in this patient population.

Top news of the day across the health care landscape

Innovations such as the Apple iPhone HealthKit could help create a smooth transition throughout the patient journey all the way to the specialty pharmacy.

An overview of scientific evidence supporting the HIV undetectable=untransmittable concept and implications for HIV prevention and treatment.

Top news of the day across the health care landscape.

Clear differences in hepatitis C virus worldwide indicate the need to increase global understanding of the virus.

Study suggests a survival benefit with ibrutinib compared with chemoimmunotherapy bendamustine plus rituximab in patients with chronic lymphocytic leukemia.